Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.

Liver international : official journal of the International Association for the Study of the Liver - 1 Dec 2018

Manoj Kumar, Nayak Suman L, Gupta Ekta, Kataria Ashish, Sarin Shiv K

Abstract excerpt

BACKGROUND & AIMS: There is scant data on use of sofosbuvir containing directly acting antiviral (DAA) regimens in chronic kidney disease (CKD) patients. Recently generic versions of DAAs have become available in low-income countries including India. The aim of this study was to study the efficacy and safety of generic sofosbuvir in combination with generic ribavirin, ledipasvir or daclatasvir in HCV-infected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Fluorenes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glomerular Filtration Rate

Share to Pyrrolidines

Share to Renal Dialysis

Share to Renal Insufficiency, Chronic

Share to Sofosbuvir

Share to Sustained Virologic Response

Source

Identifiers

PMID: 29676846
DOI: 10.1111/liv.13863

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.PMID 29676846Read ↗

Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease.Semantic proximity Read ↗

Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.Semantic proximity Read ↗

HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR.Semantic proximity Read ↗

Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease.Semantic proximity Read ↗

Efficacy and Safety of Sofosbuvir and Ledipasvir for Hepatitis C in Kidney Transplant Recipients: A Single-center Retrospective Observational StudySemantic proximity Read ↗

Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.Semantic proximity Read ↗

Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients.Semantic proximity Read ↗

Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.Semantic proximity Read ↗

Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?Semantic proximity Read ↗

Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency.Semantic proximity Read ↗

Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis.Semantic proximity Read ↗

Sofosbuvir-based regimens for HCV in stage 4-stage 5 chronic kidney disease. A systematic review with meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.